- Home
- GLUE vs TILE Comparison
GLUE vs TILE Comparison
Compare GLUE & TILE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GLUE | TILE |
|---|---|---|
| Founded | 2019 | 1973 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Home Furnishings |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 2021 | 1994 |
Fundamental Metrics
Financial Performance| Metric | GLUE | TILE |
|---|---|---|
| Price | $18.74 | $28.46 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 1 |
| Target Price | $32.00 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 644.3K | 489.4K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 0.29% |
| EPS Growth | N/A | ★ 32.43 |
| EPS | N/A | ★ 0.40 |
| Revenue | $123,672,000.00 | ★ $1,386,854,000.00 |
| Revenue This Year | N/A | $6.72 |
| Revenue Next Year | $2.45 | $5.61 |
| P/E Ratio | $72.42 | ★ $68.21 |
| Revenue Growth | ★ 63.54 | 5.41 |
| 52 Week Low | $3.90 | $18.74 |
| 52 Week High | $25.77 | $35.11 |
Technical Indicators
Market Signals| Indicator | GLUE | TILE |
|---|---|---|
| Relative Strength Index (RSI) | 49.76 | 53.66 |
| Support Level | $18.51 | $27.78 |
| Resistance Level | $21.04 | $28.89 |
| Average True Range (ATR) | 1.02 | 1.09 |
| MACD | -0.24 | -0.01 |
| Stochastic Oscillator | 33.59 | 50.78 |
Price Performance
Historical ComparisonAbout GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
About TILE Interface Inc.
Interface Inc is engaged in the design, production, and sale of carpet tiles. It also provides Luxury Vinyl tiles and rubber flooring. The company mainly targets corporate and noncorporate office markets, including government, education, healthcare, hospitality, and retailers. Its geographical segments include the Americas, Europe, and Asia-Pacific. It has two operating and reportable segments- namely Americas (AMS) and Europe, Africa, Asia and Australia (collectively EAAA). Key revenue is generated from AMS segment. Its products include: ESD, Acoustic, Extreme Wear, and Quick Installation System (nTx).